Vesilut – 20MG

Scientific Overview of Vesilut

Vesilut, also referred to as ED, is a synthetic peptide classified within the family of Khavinson bioregulators. It contains the Glu-Asp sequence, which is also present in another peptide known as Prostamax (Lys-Glu-Asp-Pro). While direct investigations on Vesilut remain limited, its similarity to Prostamax has led researchers to consider potential parallels in its action, particularly in relation to tissues of the prostate gland and urinary bladder. As a bioregulator, sometimes also termed a citomedine, Vesilut is thought to potentially interact with cellular genetic mechanisms, suggesting a role in processes related to chromatin and gene activity.

Alternative Names: ED, Vesilute, alpha-glutamylaspartic acid

Vesilut Studies and Research Data

Possible Impact on Urinary Bladder and Prostate Tissues

Although Vesilut-specific studies are scarce, research on related peptides with the Glu-Asp sequence may provide insight. In experimental contexts involving chronic inflammatory conditions in prostate tissue, these related compounds appeared to reduce swelling, hyperemia, and cellular infiltration. This suggests a potential for modulating tissue responses associated with inflammatory processes. Investigators also noted the possibility of preventing the development of sclerosis, a change linked to long-term tissue inflammation, which may have secondary importance for urinary bladder function.

Hypothesized Genetic and Chromatin Regulation

Research on peptides with structural similarity to Vesilut suggests they may participate in chromatin remodeling processes. These peptides have been described as potentially influencing chromatin condensation states, with a tendency toward decondensation in aging cells. Such a shift could, in theory, lead to reactivation of genes silenced by chromatin compaction. This proposed mechanism has been associated with increased ribosomal RNA activity, suggesting a potential for enhanced protein synthesis.

Vesilut Observations on Chromosome Stability

Some findings indicate that short peptides similar to Vesilut might increase the frequency of sister chromatid exchanges, a natural process during cell division. This could imply a contribution to genomic maintenance mechanisms. In addition, reports describe an apparent increase in nucleolus organizer regions, a marker for ribosome production, which may point to enhanced protein-building capacity in aging cells. A reduction in pericentromeric heterochromatin in specific chromosomes has also been noted, potentially releasing additional regions of genetic material for cellular use.

Conclusion

Vesilut remains a peptide with limited direct data, but analogies drawn from structurally related compounds suggest possible involvement in processes linked to tissue regulation, inflammatory responses, and chromatin activity. These preliminary insights may point to potential areas of interest for further exploration, though definitive conclusions are not yet available.

References

1. Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004 Jan;137(1):78-81. doi: 10.1023/b:bebm.0000024393.40560.05. PMID: 15085253.
2. Borovskaya, T. G., Pakhomova, A. V., Vychuzhanina, A. V., Poluektova, M. E., Fomina, T. I., Ermolaeva, L. A., ... & Neplochov, E. A. (2013). Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications. Modern Research in Inflammation, 2013.
3. Dzhokhadze TA, Buadze TZh, Gaĭozishvili MN, Baratashvili NA, Lezhava TA. [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)]. Georgian Med News. 2012 Nov;(212):76-82. Russian. PMID: 23221144.

Disclaimer:
The products mentioned are intended solely for laboratory research and in-vitro experimentation. They are not approved for human or animal use of any kind. All details provided are for educational purposes only. By purchasing from this site, you agree to comply with our Terms and Conditions.